Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

By sjmartinez • October 28, 2022

Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. Oncologist. 2022 Oct 27:oyac219. doi: 10.1093/oncolo/oyac219. Epub ahead of print. PMID: 36302223.

Tags: administrative claims, Dermatology, healthcare, Healthcare cost, immune checkpoint inhibitors, melanoma, molecular targeted therapy, Publications

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease[...]

GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic Arthritis/Psoriasis Care and Resource Limitations

Ma EJ, Boit R, Leung YY, Singla S, Fernández-Ávila D, Kalyoncu U, Armstrong AW. GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic[...]

Paradoxical melanoma in situ arising in a depigmented patch secondary to immunotherapy

Shah KS, Kang Y, Opene C. Paradoxical melanoma in situ arising in a depigmented patch secondary to immunotherapy. JAAD Case Rep. 2026 May 15;74:115-117. doi:[...]